Navigation Links
Malvern initiates European user group meetings for chemical imaging

WORCESTERSHIRE , England, 21 June 2007, Malvern Instruments has held the inaugural meeting in Europe for users of the company's near infrared chemical imaging (NIR-CI) systems. The one-day event, which took place on 13 June 2007 was hosted by AstraZeneca in Macclesfield, UK. Malvern customers from some of the world's major pharmaceutical companies joined Malvern's technical and scientific teams for a program that included oral and poster presentations on the application of NIR-CI, and the opportunity to exchange experiences and ideas.

During the first sessions, presentations from users included: 'Chemical imaging and quality by design'; 'Moving NIR chemical imaging from lab to process-based methodology'; 'Applications of NIR imaging in drug development'; and 'Content uniformity determination'. The final parts of the day were devoted to instrumentation and software, together with a session on morphological imaging.

Linda Kidder, Malvern's product manager for chemical imaging systems, felt that the day was extremely valuable. "This was our first chemical imaging user meeting in Europe and we were very pleased with the response from our customers," she said. "Attendees came from a number of different European countries and shared their experiences through oral or poster presentations. The pharmaceutical industry is currently the biggest user of Malvern's chemical imaging systems and it was good to hear more about the various applications for which they are being used." A similar meeting will be held for chemical imaging users in the United States later in the year.

Malvern's recently launched SyNIRgi system underlines the continuing migration of NIR-CI technology from its specialist roots into routine use as a highly desirable, quantitative analytical tool. The hallmarks of SyNIRgi are its rugged construction with no moving parts, modular software that enables the development of turnkey soluti
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress

Post Your Comments:
(Date:11/19/2009)... , LYON, France, Nov. 19 In re...pplying dangerous and illegal medicines, Operation...d by INTERPOL and the World Health Organization,s ... Taskforce (IMPACT) to highlight the dangers of bu...initiative resulted in a series of arrests and the...
(Date:11/19/2009)... , TAINAN, Taiwan, Nov. 19 /PRNewswire-A...ctive pharmaceutical ingredients (APIs), announced...Compound Safety Certification from,SafeBridge(R) C...harm,s,competency and proficiency in the safe hand...APIs), and applies to specific laboratories and,pr...
(Date:11/19/2009)... , DAYTON, Ohio, Nov. 19 Rivera...e partnering with leading Canadian medical imaging...nced Chest Imaging and OnGuard Chest Xray CAD. The... Riverain Medical,s products to the Canadian marke...le sales channel. ,, SoftView Enhanced Chest Im...
Breaking Medicine Technology:International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Riverain Medical Partners With The Christie Group In Canada To Offer SoftView Enhanced Chest Imaging and OnGuard Chest X-Ray CAD Technologies 2Reportlinker Adds Infections Throat Infection 61072 1Reportlinker Adds Infections Throat Infection 61072 2Reportlinker Adds Infections Throat Infection 61072 3SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 1SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 2SHRM Testifies before Senate on H1N1 and Need for Flexible Paid Leave Policies 61068 3Reportlinker Adds Cancer Vaccines 3A Measuring Market Potential 14778 1Reportlinker Adds Cancer Vaccines 3A Measuring Market Potential 14778 2
...ence demonstrating the efficacy and safety of s...ry incontinence in women.,... in the,August issue of International Urogynecolog...udy on the safety and effectiveness of tension-fre...nary incontinence (SUI) in,women. Researchers foll...
...r Greater Concordance Compared to FISH ...pany to Include Reporting for HER2 Gene Expression... by End of 2008 -, REDWOOD CITY, Calif., Sept. 6 ...ced results from two studies demonstrating,that qu...measured by the,company,s Oncotype DX(R) breast ca...
Other Medicine Technology:New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 2New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5
(Date:11/20/2009)... , WASHINGTON, Nov. 20 /PRNewswire-USNewswi...shops urged the Senate to make essential changes i...deral law on abortion funding and conscience prote...or immigrants and include strong provisions for ad... Senate health care bill an "enormous disappointme...
(Date:11/20/2009)..., CHICAGO, Nov. 20 T...he U.S. Food and Drug Administration (FDA) to esta...ing chemicals. ,, Citing concern about the saf...red without the benefit of professional consultati...id that the application of chemically based tooth ...
(Date:11/20/2009)..., LAS VEGAS, Nov. 20 ...cutive Director of the Nevada Health Care Associat...CA) commends and thanks Senate Majority Leader Har...step closer toward our goal of protecting every Ne...me care, and preserving the strength and viability...
(Date:11/20/2009)... blood pressure readings in children with chronic ...even during doctor,s office visits increasing a c...to research from Johns Hopkins Children,s Center a...pears online in the Journal of American Society of...sure measurements obtained during regular doctor v...
(Date:11/20/2009)...ers save up to one-third buying 90-day supply, stu...News) -- Buying a three-month supply of prescripti...one-month supply, according to a new study. , U...ed for 395 drugs between 2000 and 2005, and found ...ead of a one-month supply saved an average 29 perc...
Breaking Medicine News(10 mins):Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:High blood pressure easy to miss in children with kidney disease 2Health News:Three-Month Supply Lowers Drug Costs 2
...n those with no asthma history, study finds , FRID...ollege athletes have what,s known as exercise-indu...tory of the illness, a new study shows. , Previous... reported severe episodes of asthma provoked by ex...
...esis with Heparin Bioactive Surface Offers Safe, ..., COLUMBUS, Ohio, Sept. 7 Gary Ansel, MD, of Riv... physician on Wednesday, Aug.,29, to treat a commo...el successfully implanted the GORE VIABAHN Endopro...
...en at risk of having a pulmonary embolisma potenti...d first undergo a ventilation/perfusion lung scan ...angiogram, conclude authors in a paper published i... embolism, noted H. Dirk Sostman, a professor of r...
... compromised by new provisions enabling commercial... negotiated contracts, researchers warn. , A stud...th Policy at the University of Edinburgh, cautions..., The research, carried out in collaboration with...
...Driven by Growing Demand for Healthcare Informatio...,s Top Corporate Performers, CHICAGO, Sept. 7 Al...clinical software, connectivity and information,so... The list, comprised of public companies, appears ...
.... 7 Human Resources continues to,be a big cost ce...t first,for cost reductions and productivity impro...ively and efficiently? A comprehensive HR metrics...Staffing, Benefits, Relocation, LOA,FMLA, Workers,...
Other Medicine News:Health News:1 in 3 Varsity Athletes Has Exercise-Induced Asthma 2Health News:Riverside First to Offer New Treatment for Peripheral Arterial Disease 2Health News:Riverside First to Offer New Treatment for Peripheral Arterial Disease 3Health News:Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women 2Health News:Care reforms raise concerns over patient access to GP services 2Health News:Allscripts Named to FORTUNE 100 Fastest-Growing Companies List 2Health News:Allscripts Named to FORTUNE 100 Fastest-Growing Companies List 3Health News:End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver 2
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
Medicine Products: